Tech Company Financing Transactions
TG Therapeutics Funding Round
TG Therapeutics secured a $500 million funding round on 3/19/2026. Investors included Blue Owl Capital.
Transaction Overview
Company Name
Announced On
3/19/2026
Transaction Type
Debt
Amount
$500,000,000
Round
Undisclosed
Investors
Blue Owl Capital (Sandip Agarwala)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3020 Carrington Mill Blvd. 475
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Overview
TG Therapeutics was founded with one goal in mind -- to leverage scientific advances to develop the best possible treatment options for patients. Today, our focus is on translating that deep understanding of B-cells developing therapies for autoimmune diseases, with a current focus on multiple sclerosis (MS). These are conditions in which dysregulated B-cell activity plays a critical role in driving inflammation and tissue damage. By targeting B-cells with precision, our goal is to meaningfully alter the course of disease and improve how treatment fits into patients' lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Weiss
Chief Financial Officer
Sean Power
VP - Bus. Development
Adam Waldman
Browse more venture capital transactions:
Prev: 3/19/2026: PADO AI Orchestration venture capital transaction
Next: 3/19/2026: Bluesky venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs